Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients

Biol Blood Marrow Transplant. 2020 Nov;26(11):1983-1994. doi: 10.1016/j.bbmt.2020.07.027. Epub 2020 Jul 28.


There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.

Keywords: COVID-19; SARS-CoV-2; cellular therapy; hematopoietic cell transplan.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • COVID-19 / diagnosis*
  • COVID-19 / immunology
  • COVID-19 / therapy
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • COVID-19 Serotherapy
  • COVID-19 Testing
  • Cell- and Tissue-Based Therapy / methods
  • Clinical Decision-Making
  • Disease Management
  • Disinfection / methods
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Immunization, Passive
  • Immunologic Factors / therapeutic use*
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • Neoplasms / virology
  • Physical Distancing
  • Risk Assessment
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / pathogenicity
  • Time Factors


  • Adrenal Cortex Hormones
  • Antiviral Agents
  • Immunologic Factors